192 related articles for article (PubMed ID: 27192950)
1. Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.
Speeckaert R; van Geel N
Exp Dermatol; 2017 Jul; 26(7):630-634. PubMed ID: 27192950
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo therapy: restoring immune privilege?
Boniface K; Seneschal J; Taïeb A; Merched A
Exp Dermatol; 2017 Jul; 26(7):635-636. PubMed ID: 27314920
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
Willemsen M; Melief CJM; Bekkenk MW; Luiten RM
Front Immunol; 2020; 11():579022. PubMed ID: 33240267
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
5. A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Kjeldsen JW; Lorentzen CL; Martinenaite E; Ellebaek E; Donia M; Holmstroem RB; Klausen TW; Madsen CO; Ahmed SM; Weis-Banke SE; Holmström MO; Hendel HW; Ehrnrooth E; Zocca MB; Pedersen AW; Andersen MH; Svane IM
Nat Med; 2021 Dec; 27(12):2212-2223. PubMed ID: 34887574
[TBL] [Abstract][Full Text] [Related]
6. The application of nanotechnology in immune checkpoint blockade for cancer treatment.
Deng H; Zhang Z
J Control Release; 2018 Nov; 290():28-45. PubMed ID: 30287266
[TBL] [Abstract][Full Text] [Related]
7. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
Cohen BE; Manga P; Lin K; Elbuluk N
Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
[TBL] [Abstract][Full Text] [Related]
8. B7 costimulation and intracellular indoleamine 2,3-dioxygenase expression in umbilical cord blood and adult peripheral blood.
Grozdics E; Berta L; Gyarmati B; Veres G; Zádori D; Szalárdy L; Vécsei L; Tulassay T; Toldi G
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1659-65. PubMed ID: 24930629
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.
Miao X; Xu R; Fan B; Chen J; Li X; Mao W; Hua S; Li B
Sci Rep; 2018 Jan; 8(1):1605. PubMed ID: 29371688
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy.
Ravi R; Noonan KA; Pham V; Bedi R; Zhavoronkov A; Ozerov IV; Makarev E; V Artemov A; Wysocki PT; Mehra R; Nimmagadda S; Marchionni L; Sidransky D; Borrello IM; Izumchenko E; Bedi A
Nat Commun; 2018 Feb; 9(1):741. PubMed ID: 29467463
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
12. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
[TBL] [Abstract][Full Text] [Related]
14. The targeting of immunosuppressive mechanisms in hematological malignancies.
Andersen MH
Leukemia; 2014 Sep; 28(9):1784-92. PubMed ID: 24691076
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
16. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
[TBL] [Abstract][Full Text] [Related]
17. New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT; Turk MJ
Oncotarget; 2011 Sep; 2(9):684-94. PubMed ID: 21911918
[TBL] [Abstract][Full Text] [Related]
18. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ; Hamid O; Urba WJ
Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
[TBL] [Abstract][Full Text] [Related]
19. Programmed cell death protein 1 and vitiligo.
Lin X; Meng X; Song Z
Int J Dermatol; 2019 Sep; 58(9):1102-1103. PubMed ID: 31175670
[No Abstract] [Full Text] [Related]
20. Therapeutic use of anti-CTLA-4 antibodies.
Blank CU; Enk A
Int Immunol; 2015 Jan; 27(1):3-10. PubMed ID: 25038057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
